Together with the results from our genetic mouse system, these findings suggest that TGFβ signalling acts a rheostat to dictate the tumour fibroblast setpoint between universal fibroblasts and LRRC15+ myofibroblasts and may serve as a potential predictor of patient outcome. The gene discussed is TGFB1; the disease is neoplasm.